Recent Research Analysts’ Ratings Updates for Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals (NASDAQ: ARWR) recently received a number of ratings updates from brokerages and research firms:

  • 6/11/2019 – Arrowhead Pharmaceuticals was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 5/30/2019 – Arrowhead Pharmaceuticals was upgraded by analysts at TheStreet from a “d” rating to a “c+” rating.
  • 5/28/2019 – Arrowhead Pharmaceuticals had its price target raised by analysts at B. Riley from $26.00 to $32.00. They now have a “buy” rating on the stock.
  • 5/24/2019 – Arrowhead Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 5/13/2019 – Arrowhead Pharmaceuticals had its price target raised by analysts at B. Riley from $19.00 to $26.00. They now have a “buy” rating on the stock.
  • 5/9/2019 – Arrowhead Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 4/30/2019 – Arrowhead Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 4/16/2019 – Arrowhead Pharmaceuticals had its price target raised by analysts at Piper Jaffray Companies from $25.00 to $33.00. They now have an “overweight” rating on the stock.

Shares of ARWR opened at $26.37 on Thursday. Arrowhead Pharmaceuticals Inc has a 52-week low of $10.41 and a 52-week high of $27.69. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of -40.57 and a beta of 1.67.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.02. Arrowhead Pharmaceuticals had a return on equity of 6.72% and a net margin of 10.09%. The company had revenue of $48.15 million during the quarter, compared to analysts’ expectations of $45.78 million. Sell-side analysts anticipate that Arrowhead Pharmaceuticals Inc will post 0.68 earnings per share for the current fiscal year.

In other news, CFO Kenneth Allen Myszkowski sold 27,071 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $22.00, for a total value of $595,562.00. Following the transaction, the chief financial officer now owns 278,536 shares of the company’s stock, valued at $6,127,792. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Christopher Richard Anzalone sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $19.30, for a total value of $965,000.00. The disclosure for this sale can be found here. Insiders sold a total of 107,071 shares of company stock valued at $2,306,962 in the last quarter. Company insiders own 4.80% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. Teachers Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 2.5% in the third quarter. Teachers Advisors LLC now owns 170,714 shares of the biotechnology company’s stock valued at $3,273,000 after purchasing an additional 4,191 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $334,000. Rhumbline Advisers lifted its holdings in Arrowhead Pharmaceuticals by 47.1% during the 4th quarter. Rhumbline Advisers now owns 115,963 shares of the biotechnology company’s stock worth $1,440,000 after buying an additional 37,148 shares during the last quarter. SG Americas Securities LLC bought a new position in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $166,000. Finally, State Board of Administration of Florida Retirement System lifted its holdings in Arrowhead Pharmaceuticals by 10.1% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 38,552 shares of the biotechnology company’s stock worth $479,000 after buying an additional 3,542 shares during the last quarter. Hedge funds and other institutional investors own 62.31% of the company’s stock.

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Featured Story: Analyst Ratings Trading

Receive News & Ratings for Arrowhead Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply